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Dear Editor,
Alveolar Echinococcosis (EA) is a zoonosis due to the larval
stage of the fox tapeworm Echinococcus multilocuris.
Humans are dead-end hosts and are exposed through sylvatic
(fox) or domestic (cat and dog) cycles. Infection is acquired
through the fecal-oral route. The metacestodes of
E. multilocularis proliferate in the liver, inducing a Btumor-
like^ lesion that can invade the neighboring organs or spread
away from the primary lesion [1].
Until recently, Belgium was considered as a low-risk coun-
try for AE. However, in 2008, Hanosset et al. demonstrated by
necropsies of red foxes (Vulpes vulpes), a prevalence of AE at
up to 60% in some parts of Wallonia, the Southern part of
Belgium [2]. The first indigenous Belgian human AE case
was diagnosed in 1999 at the Centre Hospitalier
Universitaire (CHU) of Liege, a tertiary university hospital
in Wallonia [3]. Since this first case, other patients have been
diagnosed with EA and managed by the different departments
of the CHU Liege [4]. The aim of this study was to evaluate
the overall experience and results of the different teams of the
CHU Liege with AE and to better determine the number of
indigenous AE cases to provide this information to authorities
in charge of public health.
After University Hospital Ethical committee approval, the
authors retrospectively collecteddata from the laboratoryof clin-
ical microbiology (for Echinococcus serologies and PCR), the
hospital pharmacy in charge of supplying albendazole, and by
searching through patient files from themedico-economic infor-
mationservice. Informationwascollectedfrom1999toFebruary
2018. Belgian regulations do not require patient informed con-
sent for a purely retrospective review of medical files.
Between 1999 and February 2018, a total of 22 human
indigenous AE cases were recorded and their medical files
were studied. In all cases, the diagnosis was established based
on Echinococcus sp. serology (inhibition of hemagglutination
(Fumouze, France), ELISA specific for E. granulosus (R-
biopharm, Germany) and E. multilocularis (Bordier, Suisse)
respectively and Western Blot), clinical imaging, histopathol-
ogy and in some cases an E. multilocularis specific PCR assay
on tissue [5]. According to the criteria of Brunetti et al. [1], 11
possible and 11 confirmed cases were diagnosed.
The mean age of the patients at the time of diagnosis was
69 years (ranges: 34–85 years). Sixty-four percent of the pa-
tients were male. Some degree of immunosuppression could
be identified in 36% of cases (solid or hematologic cancers,
chronic inflammatory disease, diabetes, and chronic alcohol-
ism). At least one of the risk factors described by Conraths
et al. [6] (owning a dog and/or a cat, living in a rural zone,
working as farmer, or forestry worker) was identified in all
patients but one (data are missing). Patients lived in rural
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zones (provinces of Liege, Luxembourg and Namur). At the
time of diagnosis, three patients were asymptomatic, six pa-
tients presented with non-specific symptoms (asthenia, weight
loss), eight had symptoms related to liver invasion (abdominal
pain, jaundice, leg edema), and three presented unusual symp-
toms (lumbar pains, suppurative cutaneous lesions). In all but
one case, the patients suffered from AE liver involvement
(five in the right lobe only, six in the left lobe only, and ten
bilateral lesions). Only three patients presented with AE lim-
ited to the liver. In the other cases, invasion of the diaphragm,
the adrenal gland, the spleen, the pericardium, the mesentery,
the lumbar vertebra, the pelvic bones, or soft tissues could be
demonstrated. According to theWHO classification and PNM
staging, the lesions were classified as stage I: three patients;
stage IIIb: six patients; stage IV: 12 patients (insufficient data
in one case).
Twelve patients underwent complete hepatic and extra-
hepatic surgical resections, followed by a 2-year aldendazole
treatment, and one patient received only 6 months of
albendazole. In one patient with a R0 hepatic surgery, the 2-
year treatment was stopped because of side effects. Three
patients had an R2 (macroscopic residual disease) surgery
(inflammatory phlegmon, permanent pulmonary lesions, or
incomplete hepatic resection) followed by long-term
albendazole or mebendazole treatment. Six patients had non-
resectable AE lesions and received palliative albendazole ther-
apy, but in one patient, the treatment was stopped after 1month
because of palliative care. In another patient with non-
resectable AE lesions, the albendazole treatment was followed
for only 2 years. Side effects of albendazole (alopecia, hema-
tologic disorders, hepatic toxicity, digestive intolerance, or
neurological symptoms) are identified in 48% of the patients.
At least 14% of patients died from AE during the follow-up.
We reported herein the first cohort of indigenous AE pa-
tients in Belgium. The main limitation of this study is its
retrospective nature. Nevertheless, it demonstrates that AE
occurs in Belgium. Considering the high incidence of
E. multilocularis in red foxes and the recent reports of aberrant
cases of hepatic AE disease in dogs (indicative of high prev-
alence) [7, 8], AE is probably endemic and underestimated, at
least in Southern Belgium. In addition, the authors are con-
vinced that the lack of local experience with a new and rising
disease has lead in many cases in difficult diagnosis and per-
fectible management. In reaction to these findings, the authors
have created a multidisciplinary group including physicians
and veterinarians (ECHINO-LIEGE, www.echinococcose.be)
aimed at improving local expertise in AE diagnosis,
management and prevention, and to initiate prospective
studies both in humans and animals (in accordance with One
Health initiative), in collaboration with the Belgian health
authorities and foreign reference centers. The Belgian
authorities should be informed of this public health issue
and should favor a large systematic study in Belgian
hospitals and a follow-up study of AE prevalence in the foxes.
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